Hologic, Inc.
HOLX
Xếp hạng trong cổ phiếu
#1327
Hologic, Inc. is a medical technology company focused on designing, producing,... Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Giá cổ phiếu
$76.01
Đồng bộ lần cuối: 2026-04-07
Vốn hóa thị trường
$16.97B
Thay đổi (1 ngày)
0.00%
Thay đổi (1 năm)
2.74%
Quốc gia
US
Giao dịch Hologic, Inc. (HOLX)
Danh mục
Healthcare
Doanh thu của Hologic, Inc. (HOLX)
Doanh thu vào Dec 2025 TTM: $4.13B
Theo các báo cáo tài chính gần đây của Hologic, Inc., doanh thu hiện tại của công ty (TTM) là $4.13B. Trong năm 2024, công ty đạt doanh thu $4.03B giảm so với doanh thu năm 2023, là $4.03B. Doanh thu là tổng số tiền công ty tạo ra từ việc bán hàng hóa hoặc dịch vụ. Không giống như lợi nhuận, doanh thu không trừ chi phí.
Lịch sử doanh thu của Hologic, Inc. từ 2000 đến 2026
Doanh thu vào cuối mỗi năm
| Năm | Doanh thu | Thay đổi |
|---|---|---|
| 2026 (TTM) | $4.13B | 0.63% |
| 2025 | $4.10B | 1.74% |
| 2024 | $4.03B | 0.00% |
| 2023 | $4.03B | -17.12% |
| 2022 | $4.86B | -13.66% |
| 2021 | $5.63B | 49.14% |
| 2020 | $3.78B | 12.15% |
| 2019 | $3.37B | 4.64% |
| 2018 | $3.22B | 5.20% |
| 2017 | $3.06B | 7.98% |
| 2016 | $2.83B | 4.72% |
| 2015 | $2.71B | 6.89% |
| 2014 | $2.53B | 1.54% |
| 2013 | $2.49B | 24.45% |
| 2012 | $2.00B | 11.92% |
| 2011 | $1.79B | 6.54% |
| 2010 | $1.68B | 2.59% |
| 2009 | $1.64B | -2.23% |
| 2008 | $1.67B | 126.78% |
| 2007 | $738.37M | 59.59% |
| 2006 | $462.68M | 60.83% |
| 2005 | $287.68M | 25.79% |
| 2004 | $228.71M | 12.09% |
| 2003 | $204.04M | 7.28% |
| 2002 | $190.19M | 6.56% |
| 2001 | $178.49M | 90.40% |
| 2000 | $93.75M | 0.00% |
Doanh thu của các công ty hoặc đối thủ tương tự
| Công ty | Doanh thu | Chênh lệch doanh thu | Quốc gia |
|---|---|---|---|
| $11.03B | 167.41% |
US
|
|
| $34.74B | 741.81% |
FR
|
|
| - | - |
JP
|
|
| $20.84B | 405.02% |
US
|
|
| - | - |
CH
|
